Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity

[1]  Ning-Bo Hao,et al.  The role of miRNA and lncRNA in gastric cancer , 2017, Oncotarget.

[2]  Guido Marcucci,et al.  Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia , 2016, Nature Communications.

[3]  Y. Okuno,et al.  MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Satoru Miyano,et al.  Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.

[5]  Cheng Cheng,et al.  Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia , 2016, EBioMedicine.

[6]  Shinichi Morishita,et al.  Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults , 2016, Nature Genetics.

[7]  T. Naoe,et al.  B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia* , 2015, The Journal of Biological Chemistry.

[8]  Jun Ma,et al.  Overexpression of miR‐18a negatively regulates myocyte enhancer factor 2D to increase the permeability of the blood–tumor barrier via Krüppel‐like factor 4‐mediated downregulation of zonula occluden‐1, claudin‐5, and occludin , 2015, Journal of neuroscience research.

[9]  Leina Ma,et al.  Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. , 2014, Cancer research.

[10]  M. Zavolan,et al.  Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation , 2013, Genome research.

[11]  M. Nykter,et al.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. , 2013, The Journal of clinical investigation.

[12]  Isidore Rigoutsos,et al.  Interactive exploration of RNA22 microRNA target predictions , 2012, Bioinform..

[13]  T. Naoe,et al.  B Cell Receptor-ERK1/2 Signal Cancels PAX5-Dependent Repression of BLIMP1 through PAX5 Phosphorylation: A Mechanism of Antigen-Triggering Plasma Cell Differentiation , 2012, The Journal of Immunology.

[14]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[15]  Ferdinando Di Cunto,et al.  Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs , 2011, Cell.

[16]  T. Naoe,et al.  PAX5–PML acts as a dual dominant-negative form of both PAX5 and PML , 2011, Oncogene.

[17]  Andrew P. Stubbs,et al.  Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. , 2011, Cancer cell.

[18]  H. Horlings,et al.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.

[19]  E. Olson,et al.  Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. , 2009, Blood.

[20]  A. Usiello,et al.  Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes , 2009, EMBO reports.

[21]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[22]  M. Gearing,et al.  Regulation of Neuronal Survival Factor MEF2D by Chaperone-Mediated Autophagy , 2009, Science.

[23]  E. Olson,et al.  MEF2: a central regulator of diverse developmental programs , 2007, Development.

[24]  John McAnally,et al.  MEF2C transcription factor controls chondrocyte hypertrophy and bone development. , 2007, Developmental cell.

[25]  V. Giguère,et al.  Control of MEF2 Transcriptional Activity by Coordinated Phosphorylation and Sumoylation* , 2006, Journal of Biological Chemistry.

[26]  Xiang-Jiao Yang,et al.  Association with Class IIa Histone Deacetylases Upregulates the Sumoylation of MEF2 Transcription Factors , 2005, Molecular and Cellular Biology.

[27]  Jiing-Dwan Lee,et al.  Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. , 2004, The Journal of clinical investigation.

[28]  F. Hayakawa,et al.  Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. , 2004, Cancer cell.

[29]  T. Naoe,et al.  Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation , 2003, Oncogene.

[30]  Yang Shi,et al.  RNA Interference Reveals a Requirement for Myocyte Enhancer Factor 2A in Activity-dependent Neuronal Survival* , 2002, The Journal of Biological Chemistry.

[31]  Danielle Hulsman,et al.  Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice , 2002, Nature Genetics.

[32]  Takeshi Suzuki,et al.  New genes involved in cancer identified by retroviral tagging , 2002, Nature Genetics.

[33]  M. Privalsky,et al.  The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export , 2000, Molecular and Cellular Biology.

[34]  C. Bucana,et al.  Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. , 1997, Science.

[35]  E. Olson,et al.  Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  David D. McDonald,et al.  Programs , 1984, CL.

[37]  安田 貴彦.  B cell receptor-ERK1/2 signal cancels PAX5-dependent repression of BLIMP1 through PAX5 phosphorylation : a mechanism of antigen-triggering plasma cell differentiation , 2012 .

[38]  J. Rowley,et al.  Leukaemogenesis: more than mutant genes , 2010, Nature Reviews Cancer.

[39]  E. Olson,et al.  MEF2: a calcium-dependent regulator of cell division, differentiation and death. , 2002, Trends in biochemical sciences.